These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 19820364

  • 1. Fatigue and quality of life after risk-reducing salpingo-oophorectomy in women at increased risk for hereditary breast-ovarian cancer.
    Michelsen TM, Dørum A, Tropé CG, Fosså SD, Dahl AA.
    Int J Gynecol Cancer; 2009 Aug; 19(6):1029-36. PubMed ID: 19820364
    [Abstract] [Full Text] [Related]

  • 2. Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers.
    Fakkert IE, Mourits MJ, Jansen L, van der Kolk DM, Meijer K, Oosterwijk JC, van der Vegt B, Greuter MJ, de Bock GH.
    Cancer Prev Res (Phila); 2012 Nov; 5(11):1291-7. PubMed ID: 23009828
    [Abstract] [Full Text] [Related]

  • 3. A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer.
    Michelsen TM, Dørum A, Dahl AA.
    Gynecol Oncol; 2009 Apr; 113(1):128-33. PubMed ID: 19178933
    [Abstract] [Full Text] [Related]

  • 4. The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy.
    van der Aa JE, Hoogendam JP, Butter ES, Ausems MG, Verheijen RH, Zweemer RP.
    Fam Cancer; 2015 Dec; 14(4):539-44. PubMed ID: 26264902
    [Abstract] [Full Text] [Related]

  • 5. Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants.
    Choi YH, Terry MB, Daly MB, MacInnis RJ, Hopper JL, Colonna S, Buys SS, Andrulis IL, John EM, Kurian AW, Briollais L.
    JAMA Oncol; 2021 Apr 01; 7(4):585-592. PubMed ID: 33630024
    [Abstract] [Full Text] [Related]

  • 6. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
    Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, Isaacs C, Evans DG, Lynch H, Eeles RA, Neuhausen SL, Daly MB, Matloff E, Blum JL, Sabbatini P, Barakat RR, Hudis C, Norton L, Offit K, Rebbeck TR.
    J Clin Oncol; 2008 Mar 10; 26(8):1331-7. PubMed ID: 18268356
    [Abstract] [Full Text] [Related]

  • 7. Psychosocial factors and uptake of risk-reducing salpingo-oophorectomy in women at high risk for ovarian cancer.
    Meiser B, Price MA, Butow PN, Karatas J, Wilson J, Heiniger L, Baylock B, Charles M, McLachlan SA, Phillips KA.
    Fam Cancer; 2013 Mar 10; 12(1):101-9. PubMed ID: 23203849
    [Abstract] [Full Text] [Related]

  • 8. Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers.
    Lee YJ, Lee SW, Kim KR, Jung KH, Lee JW, Kim YM.
    J Gynecol Oncol; 2017 Jan 10; 28(1):e3. PubMed ID: 27670257
    [Abstract] [Full Text] [Related]

  • 9. Quality of life after risk-reducing salpingo-oophorectomy in women with a pathogenic BRCA variant.
    Zilski N, Speiser D, Bartley J, Roehle R, Blohmer JU, Keilholz U, Goerling U.
    J Sex Med; 2023 Dec 22; 21(1):33-39. PubMed ID: 37973412
    [Abstract] [Full Text] [Related]

  • 10. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.
    Rebbeck TR, Kauff ND, Domchek SM.
    J Natl Cancer Inst; 2009 Jan 21; 101(2):80-7. PubMed ID: 19141781
    [Abstract] [Full Text] [Related]

  • 11. Osteoporosis risk and management in BRCA1 and BRCA2 carriers who undergo risk-reducing salpingo-oophorectomy.
    Garcia C, Lyon L, Conell C, Littell RD, Powell CB.
    Gynecol Oncol; 2015 Sep 21; 138(3):723-6. PubMed ID: 26086567
    [Abstract] [Full Text] [Related]

  • 12. Factors influencing uptake and timing of risk reducing salpingo-oophorectomy in women at risk of familial ovarian cancer: a competing risk time to event analysis.
    Manchanda R, Burnell M, Abdelraheim A, Johnson M, Sharma A, Benjamin E, Brunell C, Saridogan E, Gessler S, Oram D, Side L, Rosenthal AN, Jacobs I, Menon U.
    BJOG; 2012 Apr 21; 119(5):527-36. PubMed ID: 22260402
    [Abstract] [Full Text] [Related]

  • 13. Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea.
    Kim SI, Lim MC, Lee DO, Kong SY, Seo SS, Kang S, Lee ES, Park SY.
    J Cancer Res Clin Oncol; 2016 Jan 21; 142(1):333-40. PubMed ID: 26438354
    [Abstract] [Full Text] [Related]

  • 14. Quantitative assessment of background parenchymal enhancement in breast MRI predicts response to risk-reducing salpingo-oophorectomy: preliminary evaluation in a cohort of BRCA1/2 mutation carriers.
    Wu S, Weinstein SP, DeLeo MJ, Conant EF, Chen J, Domchek SM, Kontos D.
    Breast Cancer Res; 2015 May 19; 17():67. PubMed ID: 25986460
    [Abstract] [Full Text] [Related]

  • 15. Sexual activity and functioning after risk-reducing salpingo-oophorectomy: Impact of hormone replacement therapy.
    Johansen N, Liavaag AH, Tanbo TG, Dahl AA, Pripp AH, Michelsen TM.
    Gynecol Oncol; 2016 Jan 19; 140(1):101-6. PubMed ID: 26597462
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
    Yamauchi H, Nakagawa C, Kobayashi M, Kobayashi Y, Mano T, Nakamura S, Arai M.
    Breast Cancer; 2018 Mar 19; 25(2):141-150. PubMed ID: 29019095
    [Abstract] [Full Text] [Related]

  • 17. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
    Rabban JT, Barnes M, Chen LM, Powell CB, Crawford B, Zaloudek CJ.
    Am J Surg Pathol; 2009 Aug 19; 33(8):1125-36. PubMed ID: 19440148
    [Abstract] [Full Text] [Related]

  • 18. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.
    Sherman ME, Piedmonte M, Mai PL, Ioffe OB, Ronnett BM, Van Le L, Ivanov I, Bell MC, Blank SV, DiSilvestro P, Hamilton CA, Tewari KS, Wakeley K, Kauff ND, Yamada SD, Rodriguez G, Skates SJ, Alberts DS, Walker JL, Minasian L, Lu K, Greene MH.
    J Clin Oncol; 2014 Oct 10; 32(29):3275-83. PubMed ID: 25199754
    [Abstract] [Full Text] [Related]

  • 19. Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy.
    Cohen JV, Chiel L, Boghossian L, Jones M, Stopfer JE, Powers J, Rebbeck TR, Nathanson KL, Domchek SM.
    Fam Cancer; 2012 Mar 10; 11(1):69-75. PubMed ID: 21898151
    [Abstract] [Full Text] [Related]

  • 20. Factors affecting the decision to undergo risk-reducing salpingo-oophorectomy among women with BRCA gene mutation.
    Kim D, Kang E, Hwang E, Sun Y, Hwang Y, Yom CK, Kim K, No JH, Kim YB, Kim SW.
    Fam Cancer; 2013 Dec 10; 12(4):621-8. PubMed ID: 23504064
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.